• DOI:10.1592/phco.26.6.806
Corpus ID: 26065969

Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults

@article{McDonnell2006SingleDoseR6,
  title={Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults},
  author={A. McDonnell and K. L. Lenz and D. Frei‐Lahr and J. Hayslip and P. Hall},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2006},
  volume={26}
}

A. McDonnell, K. L. Lenz, +2 authors P. Hall

Published 2006

Medicine

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Rasburicase is currently approved at a dosage of 0.15–0.2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of rasburicase for preventing or managing TLS in adults. We collected retrospective data for 11 adults… CONTINUE READING

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed